FATE

0.94736.21%
BV

Bahram Valamehr

President, CEO & Director

Dr. Bahram Valamehr, also known as Bob, Ph.D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research & Development from 2024 to January 01, 2025 and served as its Chief Research and Development Officer since March 2021 until 2024. He was Chief Development Officer of Fate Therapeutics, Inc. since August 2018 to March 2021. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate Therapeutics, Inc. until 2018 and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He is scientific leader of its iPSC Product Platform since January 2010. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. in molecular and medical pharmacology from the University of California, Los Angeles, his M.B.A. from Pepperdine University and his B.S. in biochemistry from the University of California, Los Angeles.

Positions